{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-218690","form_type":"8-K","ticker":"PRLD","cik":"0001678660","company_name":"Prelude Therapeutics Inc","filed_at":"2021-07-19T23:59:59+00:00","discovered_at":"2026-05-14T18:04:19.127970+00:00","generated_at":"2026-06-30T04:30:48.027916+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Prelude Therapeutics appoints Martin Babler as Class II director, effective July 19, 2021","bullets":["Martin Babler appointed to Board as Class II director and Audit Committee member, effective July 19, 2021.","Babler previously President and CEO of Principia Biopharma until its acquisition by Sanofi in October 2020.","Received non-incentive stock options for 36,400 shares vesting monthly over three years under 2020 Equity Incentive Plan.","Will receive standard non-employee director compensation and enter into customary indemnity agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-218690","json":"https://secwatch.observer/filing/0001193125-21-218690.json","markdown":"https://secwatch.observer/filing/0001193125-21-218690.md","text":"https://secwatch.observer/filing/0001193125-21-218690.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1678660/000119312521218690/0001193125-21-218690-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1678660/000119312521218690/d172272d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-30T04:30:48.027916+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"52113342f5","claim":"Martin Babler was appointed as Class II director at Prelude Therapeutics Inc.","evidence_excerpt":"the Board appointed Martin Babler as a Class II director and as a member of the Audit Committee of the Board, effective as of July 19, 2021","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1678660/000119312521218690/0001193125-21-218690-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}